W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Miasta: Kraków, Lublin, Skórzewo, Wrocław i 1 inne miastoWiek: od 18 latSponsor: BeOne Medicines AG
RekrutujeFaza I
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Miasta: Gdańsk, Katowice, Kraków, SkórzewoWiek: od 65 latSponsor: Janssen Cilag International
RekrutujeFaza III
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse…
Miasta: Gliwice, Katowice, Lublin, Olsztyn i 3 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza II
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma…
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 4 inne miastaWiek: od 18 latSponsor: Medical University Of Gdansk
RekrutujeFaza I/II
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Miasta: Gdańsk, Lublin, Olsztyn, Opole i 1 inne miastoWiek: od 18 latSponsor: BeOne Medicines AG
RekrutujeFaza II
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Miasta: Bydgoszcz, Katowice, Kraków, Skórzewo i 1 inne miastoWiek: od 18 latSponsor: Eli Lilly & Co.
RekrutujeFaza III
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 3 inne miastaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza II
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Miasta: Biała Podlaska, Bydgoszcz, Gdańsk, Gdynia i 8 innych miastWiek: od 18 latSponsor: Ryvu Therapeutics S.A.
RekrutujeFaza III
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Miasta: Gdańsk, Kraków, WarszawaWiek: od 18 latSponsor: Secura Bio Limited
RekrutujeFaza II/III
A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed…
Miasta: Kraków, Tomaszów Mazowiecki, Warszawa, Wrocław i 1 inne miastoWiek: od 18 latSponsor: Acrotech Biopharma Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with…
Miasta: Gdańsk, Poznań, WrocławWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Miasta: Katowice, Kraków, Lublin, Skórzewo i 4 inne miastaWiek: od 18 latSponsor: Innocare Pharma Inc.
RekrutujeFaza III
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small…
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Global Trial in APG2575 for Patients With CLL/SLL
Miasta: Bydgoszcz, Kraków, Skórzewo, ŁódźWiek: od 18 latSponsor: Ascentage Pharma Group Inc.
RekrutujeFaza III
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult…
Miasta: Bydgoszcz, Gdańsk, Katowice, Kraków i 5 innych miastWiek: od 18 latSponsor: Regeneron Pharmaceuticals Inc.
RekrutujeFaza III
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously…
Miasta: Bydgoszcz, Gdańsk, Kraków, Lublin i 6 innych miastWiek: od 18 latSponsor: Regeneron Pharmaceuticals
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With…
Miasta: Gdańsk, Katowice, Kraków, Lublin i 5 innych miastWiek: od 18 latSponsor: Regeneron Pharmaceuticals Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma…
Miasta: Bydgoszcz, Gdańsk, Katowice, Kraków i 7 innych miastWiek: od 18 latSponsor: Regeneron Pharmaceuticals Inc.
RekrutujeFaza II
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Miasta: Biała Podlaska, Brzozów, Gdynia, Kielce i 3 inne miastaWiek: od 18 latSponsor: Janssen - Cilag International
RekrutujeObserwacyjne
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
Miasta: GdańskWiek: od 18 latSponsor: International Extranodal Lymphoma Study Group (IELSG)
RekrutujeFaza III
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or…
Miasta: Bydgoszcz, Kraków, Legnica, Olsztyn i 3 inne miastaWiek: od 18 latSponsor: Grifols Therapeutics LLC
W Polsce: ZakończoneNa świecie: RekrutujeFaza I
Study of SGR-1505 in Mature B-Cell Neoplasms
Miasta: Gdańsk, Warszawa, ŁódźWiek: od 18 latSponsor: Schrodinger Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza I/II
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Miasta: WrocławWiek: do 17.99 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Miasta: Białystok, Bydgoszcz, Elbląg, Olsztyn i 3 inne miastaWiek: od 18 latSponsor: Astrazeneca AB
RekrutujeFaza III
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Miasta: Biała Podlaska, Bydgoszcz, Gdańsk, Katowice i 4 inne miastaWiek: od 18 latSponsor: Loxo Oncology Inc.
RekrutujeFaza I
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Miasta: Gdańsk, Olsztyn, Poznań, WarszawaWiek: od 18 latSponsor: BioNTech SE
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II/III
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Miasta: Gdynia, Katowice, Kraków, Lublin i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza I
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Miasta: Katowice, Kraków, Lublin, Skórzewo i 2 inne miastaWiek: od 18 latSponsor: Nurix Therapeutics Inc.
RekrutujeObserwacyjne
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
Miasta: Gdańsk, Katowice, Kraków, Lublin i 6 innych miastWiek: od 18 latSponsor: Takeda
RekrutujeFaza I
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory…
Miasta: Gdańsk, Kraków, WrocławWiek: od 18 latSponsor: F. Hoffmann-La Roche AG